
Quarterly ResultNov 13, 2026, 04:39 PM
Moleculin Biotech Q3 Net Loss Shrinks to $6.5M; Secures Nasdaq Compliance Exception
AI Summary
Moleculin Biotech, Inc. reported its third-quarter financial results for 2026, showing a reduced net loss of $6.5 million compared to $25.4 million in the prior year period. For the nine months ended September 30, 2026, the net loss was $27.0 million, an improvement from $49.1 million in the same period of 2025. The company's total assets and cash reserves have decreased. Despite receiving a Nasdaq deficiency letter for failing to meet the minimum bid price requirement, the company was granted an exception by the Hearings Panel, contingent on maintaining compliance. Moleculin Biotech also implemented two reverse stock splits in late 2025 and 2026.
Key Highlights
- Moleculin Biotech reported a net loss of $6.5 million for Q3 2026, compared to a net loss of $25.4 million in Q3 2025.
- For the nine months ended September 30, 2026, net loss was $27.0 million, compared to $49.1 million for the same period in 2025.
- Total assets decreased to $20.7 million as of September 30, 2026, from $22.1 million as of December 31, 2025.
- Total liabilities decreased to $6.2 million as of September 30, 2026, from $7.1 million as of December 31, 2025.
- Cash and cash equivalents decreased to $7.3 million as of September 30, 2026, from $8.9 million as of December 31, 2025.
- The company received $20.3 million in net cash from financing activities for the nine months ended September 30, 2026.
- Moleculin Biotech received a Nasdaq deficiency letter regarding bid price below $1.00, but was granted an exception by the Hearings Panel.
- The company effected a 1-for-20 reverse stock split on October 20, 2026, and a 1-for-25 reverse stock split on December 1, 2025.
Price Impact
More from MBRX